Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gains from Sales and Divestitures: 2017-2024

Historic Gains from Sales and Divestitures for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Dec 2024 value amounting to $581,346.

  • Rhythm Pharmaceuticals' Gains from Sales and Divestitures rose 170.60% to $581,346 in Q4 2024 from the same period last year, while for Dec 2024 it was $581,346, marking a year-over-year increase of 170.60%. This contributed to the annual value of $581,346 for FY2024, which is 170.60% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $581,346 for FY2024, which was up 170.60% from $214,837 recorded in FY2023.
  • In the past 5 years, Rhythm Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $581,346 in FY2024 and a low of $27,583 during FY2021.
  • In the last 3 years, Rhythm Pharmaceuticals' Gains from Sales and Divestitures had a median value of $214,837 in 2023 and averaged $318,243.
  • Data for Rhythm Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY surged of 474.80% (in 2022) over the last 5 years.
  • Rhythm Pharmaceuticals' Gains from Sales and Divestitures (Yearly) stood at $27,583 in 2021, then soared by 474.80% to $158,546 in 2022, then skyrocketed by 35.50% to $214,837 in 2023, then skyrocketed by 170.60% to $581,346 in 2024.